These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30220008)

  • 1. On the role of the immunoproteasome in transplant rejection.
    Basler M; Li J; Groettrup M
    Immunogenetics; 2019 Mar; 71(3):263-271. PubMed ID: 30220008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunoproteasome: a novel drug target for autoimmune diseases.
    Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation.
    Li J; Basler M; Alvarez G; Brunner T; Kirk CJ; Groettrup M
    Kidney Int; 2018 Mar; 93(3):670-680. PubMed ID: 29229189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.
    Basler M; Lindstrom MM; LaStant JJ; Bradshaw JM; Owens TD; Schmidt C; Maurits E; Tsu C; Overkleeft HS; Kirk CJ; Langrish CL; Groettrup M
    EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30279279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells.
    Kimura H; Caturegli P; Takahashi M; Suzuki K
    J Immunol Res; 2015; 2015():541984. PubMed ID: 26636107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No prolongation of skin allograft survival by immunoproteasome inhibition in mice.
    Mundt S; Basler M; Sawitzki B; Groettrup M
    Mol Immunol; 2017 Aug; 88():32-37. PubMed ID: 28582644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies.
    Bhattarai S; Ghannam K; Krause S; Benveniste O; Marg A; de Bruin G; Xin BT; Overkleeft HS; Spuler S; Stenzel W; Feist E
    J Autoimmun; 2016 Dec; 75():118-129. PubMed ID: 27522114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunoproteasome in antigen processing and other immunological functions.
    Basler M; Kirk CJ; Groettrup M
    Curr Opin Immunol; 2013 Feb; 25(1):74-80. PubMed ID: 23219269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
    Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
    Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.
    Basler M; Maurits E; de Bruin G; Koerner J; Overkleeft HS; Groettrup M
    Br J Pharmacol; 2018 Jan; 175(1):38-52. PubMed ID: 29034459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Functional and Mechanistic Roles of Immunoproteasome Subunits in Cancer.
    Tripathi SC; Vedpathak D; Ostrin EJ
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoproteasome-specific inhibitors and their application.
    Basler M; Groettrup M
    Methods Mol Biol; 2012; 832():391-401. PubMed ID: 22350900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoproteasome inhibition induces plasma cell apoptosis and preserves kidney allografts by activating the unfolded protein response and suppressing plasma cell survival factors.
    Li J; Koerner J; Basler M; Brunner T; Kirk CJ; Groettrup M
    Kidney Int; 2019 Mar; 95(3):611-623. PubMed ID: 30685098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of the immunoproteasome: current status and future directions.
    Miller Z; Ao L; Kim KB; Lee W
    Curr Pharm Des; 2013; 19(22):4140-51. PubMed ID: 23181576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome activator REGγ counteracts immunoproteasome expression and autoimmunity.
    Yao L; Zhou L; Xuan Y; Zhang P; Wang X; Wang T; Meng T; Xue Y; Ma X; Shah AS; Shang S; Ma X; Xie W; Wang H; Fu Q; Xia Y; Moses RE; Wang H; Li L; Xiao J; Zhang B; Li X
    J Autoimmun; 2019 Sep; 103():102282. PubMed ID: 31171475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.
    Basler M; Groettrup M
    Genes Immun; 2020 Nov; 21(5):273-287. PubMed ID: 32839530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patent review of immunoproteasome inhibitors.
    Ogorevc E; Schiffrer ES; Sosič I; Gobec S
    Expert Opin Ther Pat; 2018 Jul; 28(7):517-540. PubMed ID: 29865878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 20S immunoproteasome and constitutive proteasome bind with the same affinity to PA28αβ and equally degrade FAT10.
    Schmidtke G; Schregle R; Alvarez G; Huber EM; Groettrup M
    Mol Immunol; 2019 Sep; 113():22-30. PubMed ID: 29208314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormal IFN-gamma-dependent immunoproteasome modulation by Trypanosoma cruzi-infected macrophages.
    Bergeron M; Blanchette J; Rouleau P; Olivier M
    Parasite Immunol; 2008 May; 30(5):280-92. PubMed ID: 18312504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoproteasome Function in Normal and Malignant Hematopoiesis.
    Tubío-Santamaría N; Ebstein F; Heidel FH; Krüger E
    Cells; 2021 Jun; 10(7):. PubMed ID: 34206607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.